ada standards of care 2025 glp-1 receptor agonists recommendations The New ADA/EASD Type 1 Diabetes Adult Guidelines Updates from the 2025 American

What is Retatrutide

Diabetes mellitus is a major risk factor for both cardiovascular and chronic kidney disease (CKD) while CKD is also associated with cardiovascular morbidity

Time-of-onset analysis revealed no consistent mechanism for the latency of SSIBs in patients receiving GLP-1RAs

Results At 1 year, patients achieved significant weight loss with a median total weight loss (%TWL) of 25.5% and a median excess weight loss (%EWL) of 66.3% compared to 16.6% and 40.8%, respectively, at treatment initiation with BMI reduction of 3.7 kg/m2

Insurers raised cost-sharing sharply for GLP-1s in recent years and also increased use of prior authorization.

Semaglutide (Ozempic)